Psychedelics
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic […]
Lobe Sciences Provides Corporate Update to Investors and Stakeholders
Vancouver, British Columbia–(Newsfile Corp. – September 13, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company: Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts, We are pleased to say […]
KetamineOne Continues to Build Out Leading North American Presence
Ketamine has become a promising mental health therapeutic in recent years. With the FDA’s approval of Spravato, for example, the treatment has the potential to alleviate depressive symptoms in as little as 24 hours — far less time than traditional Selective Serotonin Reuptake Inhibitors or other therapies. And researchers are just beginning to understand and […]
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
The investment provides CaaMTech with capital to advance compounds from its library into clinical trials ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) — CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round, led by Noetic Fund. The oversubscribed round of funding will be […]
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine […]
Enveric & MagicMed: Combining Drug Discovery with Clinical Expertise
Enveric Biosciences Inc.’s (NASDAQ: ENVB) focus has been on discovering and developing cannabinoid-based therapeutics for patients suffering from the side effects of cancer treatments. With the acquisition of MagicMed Industries, the company also sees an opportunity in cancer-related distress from anxiety, depression, and PTSD. Emerging research suggests that psychedelics could play a key role […]
TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has selected Treatment-Resistant Depression (“TRD”) and End of […]
Novamind Uplists to OTCQB Venture Market
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that, effective today, its common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market (the “OTCQB”), a U.S. trading platform operated […]
NAPLES, Fla., Sept. 9, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that Dr. Joseph Tucker, MagicMed Industries’ (“MagicMed”) Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and Virtual Gravitas Health Reimagined Investor Day. […]
Ketamine One Signs LOI for Two Ketamine Infusion Clinics in Texas
The Arrangement Bolsters the Company’s Proposed Network of Six Clinics in the United States VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased […]
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188 (“N,N-Dimethyltryptamine or “DMT”), increased the growth of cortical neurons by 40% with […]
Filament Health Shares to Commence Trading on the OTC Market
VANCOUVER, BC, Sept. 7, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (OTC Pink: FLHLF) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, today announced that it received notification from the Financial Regulatory Authority (“FINRA”) that its shares are qualified to commence trading on the OTC Pink Market (the “OTC”) in the United States […]
Ehave’s Covid Passport provides small businesses a tool to verify Covid-19 vaccination, and a suite of products to improve both the mental and overall health of individuals. MIAMI, Sept. 07, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today its […]
Silo Pharma Expanding Drug Delivery IP Portfolio
While inflammation in general contributes to a wide range of diseases, swelling of the central nervous system (CNS) is associated with conditions including Parkinson’s disease, multiple sclerosis, chronic back pain, bipolar disorder, cancer cachexia, Alzheimer’s disease, and many more. Treatment of inflammation in the CNS is difficult due to the role of the blood-brain barrier […]
Ketamine One to Deploy Cognetivity’s Integrated Cognitive Assessment Tool
Ketamine One and Cognetivity Also Sign LOI to Collaborate on Mental Health Assessment Tools VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased […]
Biotech Veteran David Kideckel Joins the Board of PharmaDrug
Toronto, Ontario–(Newsfile Corp. – August 30, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that David Kideckel will be joining the board […]
Ketamine One Subsidiary IRP Health Expands With New Veteran-Focused Clinics
Integrated Rehab and Performance Re-Branded as IRP Health to Better Reflect its Planned Evolution into a Multidisciplinary Business VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental […]
Psychedelic Experience: Treating the Trip that Never Ends
Psychedelics, including ketamine, psilocybin, and LSD, are gaining traction in the mental health industry as they have been found to be potentially beneficial for conditions ranging from depression to anxiety to PTSD to alcoholism. As psychedelics are entering the mainstream of science and health, more is being discovered about a condition called Hallucinogen Persisting […]
Board Includes Diverse Medical Professionals: Neuroscientist, Anesthesiologist, Addiction Psychiatrist, Interventional Pain Physician and Others to Serve as Thought Leaders and Advisors for Delic Subsidiaries VANCOUVER, BC, Aug. 26, 2021 /PRNewswire/ – Delic Holdings Corp (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform today announced the formation of a Medical Advisory Board. The diverse advisory […]
NeonMind Announces DTC Eligibility
VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that its common shares listed on the OTCQB under the symbol “NMDBF” are now eligible for […]
HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
The partnership will further industry growth for naturally derived psilocybin VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, recently signed […]
Toronto, Ontario–(Newsfile Corp. – August 25, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a Clinical […]
Silo Pharma Advances Psychedelic Patent Portfolio
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin. “Each of […]
NEW YORK, Aug. 24, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making. MindMed and Forian will collaborate to develop best practices for […]
CB Therapeutics Expands Biomanufacturing IP Portfolio
CB Therapeutics has been awarded two additional patents for its breakthrough biosynthesis platform. These patents cover new cellular agriculture advances for producing high value compounds. CB Therapeutics is building the largest collection of biosynthetic cannabinoids, psychedelics, and their analogs, the PsyVault™. SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is a leading biosynthesis company focused on the research and […]
Moksha Digital is the creator of the FDA Cleared CuriePACS (Picture Archival and Communication System) and CurieRIS (Radiological Information System) solutions designed to meet the needs of the Radiologists, the Clinicians and the Surgeons. Moksha Digital creates software to help healthcare institutions drive quality higher and costs lower by providing Picture Archival and Communication System […]
Ehave Files 6-K Disclosing Research Project Agreement
MIAMI, Aug. 24, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that it has filed a Form 6-K with the SEC disclosing the Company entered into a Research Project Agreement with The University of Melbourne o gather data and […]
VANCOUVER, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has established a Medical Advisory Board (“ MAB ”) to help guide […]
Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” Products
TORONTO and CAPE TOWN, South Africa, Aug. 18, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the commencement of online sales and distribution of its premium range of functional mushroom products, GOODMIND™. […]
TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness ” or the “ Company ”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, today announced a $3 million national distribution agreement with Texas-based distribution and advertising company One Light Enterprises LLC. (“ One Light ”) for Silo Wellness’ portfolio of Marley One branded mushroom products […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
True Leaf is a Licensed Producer of cannabis preparing to launch a program to provide seed-to-shelf solutions for micro-cultivators.
Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
